Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

Michael H. Woo, Jennifer K. Peterson, Catherine Billups, Hua Liang, Mary Ann Bjornsti, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Purpose: Irofulven, a novel chemotherapeutic agent with a broad spectrum of activity, is effective against preclinical models of pediatric tumors. The cytotoxic activity of irofulven is augmented when combined with agents that interact with DNA topoisomerase I; however, none of the reported studies have used the protracted dosing schedule found to be active clinically in treatment of childhood cancers. The objective of this study was to evaluate the antitumor activity of irofulven in combination with irinotecan administered on a protracted schedule in a panel of pediatric solid tumor xenografts. Methods: Irofulven and irinotecan were evaluated alone or in combination against eight independent xenografts, which included childhood brain tumors (n=5), neuroblastoma (n=1), and rhabdomyosarcoma (n=2). Irofulven was administered i.v. daily for 5 days with courses repeated every 21 days for a total of three cycles. Doses of irofulven ranged from 1.33 to 4.6 mg/kg. Irinotecan was given i.v. daily for 5 days each week for 2 weeks repeated every 21 days for three cycles at doses between 0.28 and 1.25 mg/kg. Results: Irofulven and irinotecan, given as single agents, induced few responses in pediatric solid tumor xenografts at the selected doses. At the same doses, irofulven in combination with irinotecan demonstrated superior antitumor activity, inducing complete responses in seven of the eight xenograft lines. Conclusions: These studies show that the cytotoxic activity of irofulven is greater when combined with protracted administration of irinotecan. Although the systemic exposure of irofulven required to induce objective responses in this panel of pediatric solid tumors was in excess of that achievable in patients receiving maximally tolerated doses using this schedule of drug administration, the enhanced activity of irofulven in combination with irinotecan supports the pursuit of alternative administration strategies and combinations.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalCancer chemotherapy and pharmacology
Volume55
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Keywords

  • Irinotecan
  • Irofulven
  • Pediatrics
  • Solid tumors
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models'. Together they form a unique fingerprint.

Cite this